Clinical Trial Update: Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography [Phase 2]

View source ↗

Summary

Phase 2 trial of CMX-2043 evaluated safety and efficacy for protecting the heart and kidneys in patients undergoing coronary angiography; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-st-elevation Myocardial Infarction
• Unstable Angina

Drugs mentioned

• CMX-2043 (CMX-2043)

Snippet

Sponsor: Ischemix, LLC | Conditions: Non STEMI, Unstable Angina | Phase 2 | Status: COMPLETED